Ranolazine Improves Glycemic Variability and Endothelial Function in Patients with Diabetes and Chronic Coronary Syndromes: Results from an Experimental Study

Table 3

Flow-mediated dilation and oxidative stress at baseline and after 3-month follow-up.

	Ranolazine			No ranolazine
	Baseline	3 months	value	Baseline	3 months	value
Baseline artery diameter (cm)			0.008			0.411
Hyperemia-induced diameter (cm)			<0.001			0.280
FMD (%)			0.039			0.445
d-ROMs (U.CARR)			0.075			0.647
PAT (U.Cor.)			0.007			0.888

compared with 3-month results in the ranolazine cohort; Values are . FMD: flow-mediated dilation; d-ROMs: derivative reactive oxygen metabolites; PAT: plasma antioxidant test.